论文部分内容阅读
目的研究培门冬酶治疗结外NK/T细胞淋巴瘤的疗效以及安全性,为临床用药提供依据。方法从2008年1月至2013年6月来我院就诊的结外NK/T细胞淋巴瘤(鼻型)患者中选择符合研究条件的患者30例,并将其随机分为实验组和对照组,每组患者各15例。实验组患者接受培门冬酶联合吉西他滨、奥沙利铂、地塞米松治疗;对照组患者接受左旋门冬酰胺酶联合吉西他滨、奥沙利铂、地塞米松治疗。同时对实验组和对照组均结合相同手段的放疗,比较两组患者的治疗有效率及不良反应的发生率。结果 30例患者的总有效率为90%(27/30)。对照组的有效率为86.7%(13/15),实验组的有效率为93.3%(14/15),差异无统计学意义(χ2=0.549,P=0.432)。对照组患者3~4度消化道反应、高血糖、过敏反应的发生率均高于实验组(P<0.05)。结论培门冬酶治疗结外NK/T细胞淋巴瘤的临床效果较好,且不良反应发生率比较低,在临床上有较高的应用价值。
Objective To study the efficacy and safety of pemetrexed in the treatment of extranodal NK / T cell lymphoma and provide the basis for clinical use. Methods From January 2008 to June 2013, 30 patients with extranodal NK / T cell lymphoma (nose type) treated in our hospital were enrolled and randomly divided into experimental group and control group , Each group of 15 patients each. Patients in the experimental group were treated with pegaspargase combined with gemcitabine, oxaliplatin and dexamethasone; patients in the control group were treated with L-asparaginase combined with gemcitabine, oxaliplatin and dexamethasone. At the same time, the experimental group and the control group were combined with the same means of radiotherapy, the treatment efficiency and adverse reactions in both groups were compared. Results The total effective rate of 30 patients was 90% (27/30). The effective rate was 86.7% (13/15) in the control group and 93.3% (14/15%) in the experimental group, with no significant difference (χ2 = 0.549, P = 0.432). Patients in the control group had 3-4 grade gastrointestinal reactions, hyperglycemia, and anaphylaxis rates higher than those in the experimental group (P <0.05). Conclusion The clinical efficacy of pemetrexed in the treatment of extranodal NK / T cell lymphoma is good, and the incidence of adverse reactions is relatively low, which has a high clinical value.